8月19日，波士顿科学盘中上涨3.21%，报52.31美元/股，成交额1.59亿美元。
消息面上，波士顿科学新一代热蒸汽治疗设备Rezūm EVO正式获得中国国家药监局批准，用于治疗前列腺增生。中国成为该产品全球首批获批市场，产品将在波士顿科学上海临港工厂实现本土化生产，专门供应中国市场。该审批体现了公司在中国市场的深度布局，有助于泌尿外科业务在亚太区的增长。此外，公司此前发布的第二季度财报中，调整后每股收益0.86美元超出市场预期0.83美元，营收54.42亿美元同样超预期，介入心脏病学和神经调节业务表现强劲。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.